CTLA4
(Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))
蛋白类型
Recombinant
生物活性
Active
产品特性
AA 37-160
宿主
Cynomolgus, 猕猴
资源
HEK-293 Cells
标记
This CTLA4 protein is labelled with His tag.
序列
AA 37-160
产品特性
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 14.1 kDa. The protein migrates as 18-23 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
CTLA4
宿主: 豚鼠
宿主: Yeast (Pichia pastoris)
Recombinant
> 90 % as determined by reducing SDS-PAGE.
Active
限制
仅限研究用
状态
Lyophilized
缓冲液
PBS, pH 7.4
注意事项
Please avoid repeated freeze-thaw cycles.
储存条件
-20 °C
储存方法
No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
抗原
CTLA4
(Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))
CTLA-4 Protein, CTLA4 Protein, CD152 Protein, Cd152 Protein, Ctla-4 Protein, Ly-56 Protein, CD Protein, CELIAC3 Protein, GRD4 Protein, GSE Protein, IDDM12 Protein, sCTLA4 Protein, cytotoxic T-lymphocyte associated protein 4 Protein, cytotoxic T-lymphocyte-associated protein 4 Protein, CTLA4 Protein, Ctla4 Protein
背景
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.